Past Event
Friends of Cancer Research-Brookings Conference on Clinical Cancer Research
To address critical issues in the development of new oncology drugs, Friends of Cancer Research and the Engelberg Center for Health Care Reform will co-host the seventh annual Conference on Clinical Cancer Research. This annual conference brings together leaders in cancer drug development from federal health and regulatory agencies, academic research, and the private sector for focused discussions on key issues surrounding the development and regulation of cancer drugs and therapies. This year’s conference will feature three panels that will propose unique approaches toward current challenges in drug development.
Agenda
Panel One: Potential Strategies for Non-Randomized Evaluation of New Drugs
Deborah Armstrong
Professor of Oncology - Johns Hopkins Kimmel Cancer Center
Mace Rothenberg
Senior Vice President, Clinical Development/Medical Affairs - Pfizer
Rich Simon
Chief, Biometric Research Branch - National Cancer Institute
Josh Sommer
Executive Director - Chordoma Foundation
Gideon Blumenthal
Clinical Team Leader - U.S. Food and Drug Administration
Richard Pazdur
Director, Office of Oncology Products - U.S. Food and Drug Administration
Panel Two: Improving Evidence Developed From Population-Level Experience with Targeted Agents
Richard Schilsky
Chief Medical Officer - American Society of Clinical Oncology
Jane Perlmutter
Founder and President - Gemini Group
Vincent Miller
Chief Medical Officer - Foundation Medicine, Inc.
Sam Nussbaum
Executive Vice President, Clinical Health Policy and Chief Medical Officer - WellPoint, Inc.
Dane Dickson
Director of Clinical Science - MoIDX, Palmetto GBA
Richard Pazdur
Director, Office of Oncology Products - U.S. Food and Drug Administration
Panel Three: Consideration of Summary Review of Supplemental NDA/BLA Submissions in Oncology
Rachel Sherman
Principal, Drug and Biological Drug Products - Greenleaf Health LLC
Tatiana Prowell
Breast Cancer Scientific Lead, Division of Oncology Products 1, Office of Hematology & Oncology Products - U.S. Food and Drug Administration
Katherine Sugarman
Senior Director, Global Regulatory Affairs, Oncology - Eli Lilly
Laurie Strawn
Associate Director, Worldwide Regulatory Strategy - Pfizer
Kannan Natarajan
Senior Vice President and Global Head - Novartis Pharmaceuticals
Raji Sridhara
Acting Director, Division of Biometrics V - U.S. Food and Drug Administration
Robyn Lim
Senior Science Advisor - Health Canada
Morning Keynote: A Path to 21st Century Cures
Hon. Fred Upton
Chairman - United States House of Representatives, Energy & Commerce Committee
Lunch Keynote: State of FDA's Breakthrough Therapy Designation
Janet Woodcock
Director, Center for Drug Evaluation and Research - US Food and Drug Administration
Welcome
Ellen Sigal
Chairperson and Founder - Friends of Cancer Research
More Information
Contact
To subscribe or manage your subscriptions to our top event topic lists, please visit our event topics page.
